Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout

John Carroll

Editor & Founder

Amber Tong

Five months after MyoKardia $MYOK swept its late-stage pivotal on its lead heart drug — highlighting its success with a precision med approach to cardiology …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout

John Carroll

Editor & Founder

Amber Tong

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Bris­tol My­ers of­fers a big pre­mi­um to reel in MyoKar­dia's car­dio pipeline with a $13B buy­out

Editor & Founder

Sign up to read this article for free.

Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout